TD Cowen analyst Tyler Van Buren maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares closed last Friday at $35.63.
Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Travere Therapeutics, and Spyre Therapeutics. According to TipRanks, Van Buren has an average return of 4.6% and a 46.58% success rate on recommended stocks.
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $50.00, representing a 40.33% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $47.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $44.32 and a one-year low of $11.75. Currently, BridgeBio Pharma has an average volume of 1.83M.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BBIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BridgeBio Pharma (BBIO) Company Description:
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Read More on BBIO:
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio price target raised to $46 from $42 at Citi
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- BridgeBio reports Q4 EPS (96c), consensus (91c)
- BridgeBio, Kyowa Kirin announces partnership
